Revenue growth 15-20% over three years
Management reiterated long-term revenue growth guidance of 15-20% CAGR, supported by strong pharma relationships and pipeline.
SAILIFE / guidance tracker
Keep management guidance in view.
Sai Life Sciences · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
EBITDA margin 28-30% over three years
Aspirational margin range of 28-30% maintained, with FY26 margin at 30% but new capacity inefficiencies expected.
Capex ₹1,100-1,300 crore in FY27
Capex guided at ₹1,100-1,300 crore, with 75% for capacity expansion (including 225kL reactor capacity) and 25% for capabilities/AI.
H2 FY27 stronger than H1
Due to new capacities coming on stream progressively, second half of FY27 expected to be stronger than first half.